Lyve1 polyclonal antibody (DyLight 549)
- Known as:
- Lyve1 pab (anti-) (DyLight 549)
- Catalog number:
- PAB14998
- Product Quantity:
- 100 uL
- Category:
- -
- Supplier:
- Abno
- Gene target:
- Lyve1 polyclonal antibody (DyLight 549)
Related genes to: Lyve1 polyclonal antibody (DyLight 549)
- Gene:
- ASPM NIH gene
- Name:
- abnormal spindle microtubule assembly
- Previous symbol:
- MCPH5
- Synonyms:
- Calmbp1, ASP, FLJ10517, FLJ10549
- Chromosome:
- 1q31.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-08-13
- Date modifiied:
- 2016-10-05
- Gene:
- C6orf223 NIH gene
- Name:
- chromosome 6 open reading frame 223
- Previous symbol:
- -
- Synonyms:
- MGC45491
- Chromosome:
- 6p21.1
- Locus Type:
- gene with protein product
- Date approved:
- 2007-12-19
- Date modifiied:
- 2016-09-30
- Gene:
- C12orf66 NIH gene
- Name:
- chromosome 12 open reading frame 66
- Previous symbol:
- -
- Synonyms:
- FLJ32549
- Chromosome:
- 12q14.2
- Locus Type:
- gene with protein product
- Date approved:
- 2008-06-19
- Date modifiied:
- 2019-02-18
- Gene:
- ELOF1 NIH gene
- Name:
- elongation factor 1 homolog
- Previous symbol:
- -
- Synonyms:
- MGC4549, ELF1
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2005-03-25
- Date modifiied:
- 2016-02-10
- Gene:
- EXD3 NIH gene
- Name:
- exonuclease 3'-5' domain containing 3
- Previous symbol:
- -
- Synonyms:
- LOC54932, FLJ20433, mut-7
- Chromosome:
- 9q34.3
- Locus Type:
- gene with protein product
- Date approved:
- 2009-03-04
- Date modifiied:
- 2014-11-19
Related products to: Lyve1 polyclonal antibody (DyLight 549)
Related articles to: Lyve1 polyclonal antibody (DyLight 549)
- Border-associated macrophages (BAMs) represent a specialized population of tissue-resident immune cells strategically positioned at the critical interfaces between the central nervous system (CNS) and peripheral circulation, including the meninges, choroid plexus, and perivascular spaces. As frontline sentinels of the neuroimmune system, BAMs perform essential functions in immune surveillance, barrier integrity maintenance, and homeostatic regulation, yet their unique biology and disease-associated roles remain incompletely characterized compared to parenchymal microglia. This review aims to synthesize current knowledge on BAM ontogenetic origins, compartment-specific heterogeneity, transcriptional programs, and functional outputs in both health and neurological disorders. We conducted a comprehensive literature analysis integrating findings from lineage tracing studies, single-cell RNA sequencing, spatial transcriptomics, and functional interrogation in animal models of disease. The results reveal that BAMs exhibit remarkable cellular diversity shaped by distinct ontogenetic origins-primarily yolk sac-derived erythro-myeloid progenitors with variable contributions from fetal liver and postnatal monocytes depending on anatomical compartment. Compartment-specific marker combinations (CD206, LYVE1, CD163, MHCII) define functionally distinct subsets, and core transcriptional regulators including PU.1 and IRF8 maintain BAM identity while CSF-1/IL-34-CSF1R signaling governs survival and renewal. In neurological disorders including ischemic stroke, Alzheimer's disease, multiple sclerosis, and brain tumors, BAMs display pronounced double-edged roles, transitioning from protective homeostatic guardians to pathogenic drivers depending on disease stage and microenvironmental context. This comprehensive analysis establishes a unified framework for understanding BAM biology and identifies critical opportunities for developing subset-specific therapeutic strategies targeting these interface macrophages in neurological diseases. - Source: PubMed
Publication date: 2026/07/03
Liu XuetingLi MingyueWei ZengrongShang TongZou Wei - Hyaluronan (HA) receptors are expressed in a wide variety of different tissues and have long been known to support the critical cellular functions of adhesion and motility, in addition to a range of different physiological and pathological processes, including immunity, inflammation and tumour metastasis. In recent years, LYVE-1, an HA receptor largely but not exclusively restricted to the endothelia of lymphatic capillaries, has been shown to mediate the entry of immune cells through lymphatic endothelial junctions by engaging with their surface HA glycocalyx, itself anchored to the immune cell membrane by the closely related receptor CD44. Although similar to CD44 in primary sequence, LYVE-1 is functionally distinct, with a mutually exclusive pattern of tissue expression and a marked dependence on avidity for engagement with the long chains of HA-achieved primarily through receptor clustering. Here, we review key data that have defined the in vitro and in vivo functions of LYVE-1, including recent high-resolution crystal structures that have revealed its unusual and reversible "sliding" mode of interaction with HA, as distinct from the conventional "sticking" interaction in CD44. Lastly, we consider the emerging functions of LYVE-1 in sites beyond the lymphatics, namely tissue-resident macrophages and the specialised blood vessels of certain organs, and its potential as a therapeutic target. - Source: PubMed
Publication date: 2026/05/26
Jackson David G - There are a few molecules that are regularly used as markers for lymphatic endothelial cells (LECs) such as the adhesion molecule CD31/PEACAM1, the transcription factor PROX1, the Vascular Endothelial Growth Factor Receptor-3 (VEGFR3/), the glycoprotein podoplanin, and the hyaluronan receptor LYVE1. However, none of the molecules are exclusively expressed in LECs, and there is molecular and functional heterogeneity of LECs in initial lymphatics, lymphatic collectors and lymph nodes. Therefore, a combination of markers must be applied to identify lymphatics. This is particularly true for the characterization of conditions such as lymphatic malformations or cancers, in which the molecular profile of vessels may be variable or abnormal. Here we present two molecules that can help distinguish between endothelial cells of blood and lymphatic vessels: the scaffold protein liprin β-1 (PPFIBP1) and the intermediate filament synemin. We collected own data on the RNA and protein expression of the two molecules in humans, and studied publicly available databases. PPFIBP1 appears to be a suitable marker of LECs in initial lymphatics, collectors and lymph nodes, while synemin appears to be more restricted to initial lymphatics. We hope this will stimulate monoclonal antibody development and help expand the range of LEC markers in health and disease. - Source: PubMed
Publication date: 2026/06/10
Becker JürgenWilting Jörg - CCN1, also called Cyr61, is a secreted protein involved in diverse biological processes including senescence. While elevated in brains of Alzheimer's disease (AD) models and patients, CCN1/Cyr61 levels in cerebrospinal fluid (CSF) remain unclear. Using a high-sensitive quantification method, we analyzed CSF samples from 79 subjects (age: 77.7 ± 5.4 years [63-94], MMSE: 20.1 ± 5.9 [0-30]) who underwent CSF tap test. CCN1/Cyr61 showed strong associations with Aβ40 (r = 0.67), Aβ42 (r = 0.48), Aβ42/40 ratio (r = -0.53), and phospho-tau levels (r = 0.53) (all; < 0.0001). CCN1/Cyr61 also moderately associated with glial markers, YKL-40, sTREM2, CD163, and a lymphatic endothelial marker, LYVE-1 (r ≈ 0.4). While these cellular markers also associated with Aβ and phospho-tau, effects were much weaker. Collectively, CCN1/Cyr61 is associated with Aβ species and p-tau in CSF. These associations are considerably stronger than those observed with typical glial or other cellular markers, providing a clue to understanding the link between senescence and AD pathology at the levels of fluid biomarkers. - Source: PubMed
Publication date: 2026/06/05
Shinohara MitsuruMomota HiroyukiSaito TsuyoshiTakenobu ChisakoKasuga KensakuGheni GhupurjanKawai KaoriMorishima MahoSaito YukoShindo AkihiroYasuno FumihikoIkeuchi TakeshiFukumori AkioSato Naoyuki - The brain lymphatic system clears metabolic waste from neural tissue, maintains extracellular fluid homeostasis, and supports brain function. Its dysfunction is associated with neurodegenerative disorders and neuroinflammation. Thus, lymphatic efflux is essential for brain physiology. This study evaluated the superficial and deep vascular structures involved in extracranial lymphatic drainage of the human brain. Immunohistochemistry (IHC) and Western blot analyses were used to identify LVs associated with superficial (Trolard and Labbé) and deep (internal cerebral and vein of Galen) cerebral veins and the internal jugular vein (IJV). Furthermore, the anterior (ACA), middle (MCA), internal carotid (ICA), and vertebral (VA) arteries were analyzed for LYVE-1 (a lymphatic endothelial marker) and CD31 (a vascular endothelial marker). Western blotting was used to confirm the IHC findings. The IHC analyses showed LVs in the adventitia of the vessels accompanying the ICA, VA, and IJV. However, no true LVs were observed along the ACA and MCA, nor along the superficial or deep venous structures of the brain, except the IJV. The diameters of LVs ranged from 40.1-3612.7 µm (Mean ± SD: 990.0 ± 1448.6) accompanying the ICA, 11.3-221.4 µm (Mean ± SD: 67.1 ± 72.7 µm) accompanying the VA, and 5.0-264.7 µm (Mean ± SD: 40.4 ± 61.3 µm) accompanying the IJV. Western blotting confirmed the presence of LVs accompanying the ICA, VA, and IJV. Understanding the circulation of the human brain lymphatic system can provide insights into neurological disease and new therapeutic approaches. - Source: PubMed
Publication date: 2026/06/16
Altınöz DamlasuÖzkan MazharMortaş Ferdane NilayPirdal BeyzaAslıyüksek HızırÇakır HalitÇavdar Safiye